We develop a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.
Serine ß-lactamase Inhibitor (SBLi)
We develop a novel serine ß-lactamase inhibitor with excellent coverage against KPC superbugs and best in class potential vs OXA producers including Acinetobacter.
Pseudomonas Elastase Inhibitors (PEi)
A program powered by CARB-X seeking to develop a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the treatment of chronic respiratory infections in Cystic Fibrosis patients.
About Antabio
WHAT WE DO
We are a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
